source
- FDA grants accelerated approval for Etcamah combo therapy for advanced HR-positive, HER2-negative breast cancerThe U.S. Food and Drug Administration announced accelerated approval of Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for adult patients with hormone-receptor-positive, HER2-negativ…
- FDA alerts hospitals to purge cassette fault in Abiomed Impella controllersThe FDA issued an Early Alert after identifying a problem with the purge cassette recognition in Abiomed’s Automated Impella Controllers, which could cause prolonged delays in mechanical circulator…